NCT06138080

Brief Summary

The purpose of this study is to examine the applicability of contrast enhanced voiding ultrasonography in diagnosing vesicoureteral reflux (VUR) in pediatric patients compared to direct isotope cystography. The aim of the study is to find a modality allowing the accurate diagnosis of VUR and the classification of the degree of VUR with the least possible harm from the examinations. The investigators recruit 100 under 6 years old patients who have had at least 2 culture positive urinary tract infections. Exluding criteria are abnormal bladder function and posterior uretral valves. The investigators perform direct isotope cystography and contrast enhanced voiding urosonography during the same day to diagnose and grade VUR. The investigators use standardized volume and speed of bladder filling. The examinations are done by a radiologist and an isotope specialist and they are blinded to the result of the other examination.

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
100

participants targeted

Target at P50-P75 for not_applicable

Timeline
60mo left

Started May 2022

Longer than P75 for not_applicable

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress45%
May 2022May 2031

First Submitted

Initial submission to the registry

October 3, 2021

Completed
7 months until next milestone

Study Start

First participant enrolled

May 15, 2022

Completed
1.5 years until next milestone

First Posted

Study publicly available on registry

November 18, 2023

Completed
6.5 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 15, 2030

Expected
12 months until next milestone

Study Completion

Last participant's last visit for all outcomes

May 1, 2031

Last Updated

November 18, 2023

Status Verified

April 1, 2023

Enrollment Period

8 years

First QC Date

October 3, 2021

Last Update Submit

November 13, 2023

Conditions

Outcome Measures

Primary Outcomes (1)

  • Diagnostic accoracy of CEVUS in detecting vesicoureteral reflux

    The primary outcome measure of this study is the diagnostic accoracy of CEVUS in detecting vesicoureteral reflux compared to direct isotope cystography, expressed as the sensitivity and specificity of each method

    1 day

Secondary Outcomes (1)

  • Incidence and severity of adverse effects associated with CEVUS

    1 year

Study Arms (1)

VUR diagnostics

OTHER
Diagnostic Test: Contrast-enhanced voiding ultrasonography (CEVUS), Direct isotope cystography

Interventions

We have no specific intervention. We investigate different diagnostic modalities of VUR.

VUR diagnostics

Eligibility Criteria

Age0 Years - 6 Years
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17)

You may qualify if:

  • under 6 years old patients who have had at least 2 culture positive urinary tract infections

You may not qualify if:

  • abnormal bladder function
  • posterior uretral valves

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Turku University hospital

Turku, 20521, Finland

RECRUITING

MeSH Terms

Conditions

Vesico-Ureteral Reflux

Condition Hierarchy (Ancestors)

Urinary Bladder DiseasesUrologic DiseasesFemale Urogenital DiseasesFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital DiseasesMale Urogenital Diseases

Central Study Contacts

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Masking Details
The radiologist and the isotope specialist are not aware of the results of previous VUR investigations.
Purpose
DIAGNOSTIC
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER GOV
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Principal investigator

Study Record Dates

First Submitted

October 3, 2021

First Posted

November 18, 2023

Study Start

May 15, 2022

Primary Completion (Estimated)

May 15, 2030

Study Completion (Estimated)

May 1, 2031

Last Updated

November 18, 2023

Record last verified: 2023-04

Locations